Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... marrow failure . PNH is due to a somatic, acquired mutation in the X-linked phosphatidylinositol glycan class A (PIG-A) gene, ...

    Research Article last updated 10/02/2012 - 9:57am.

  2. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry.

    ... stem cell disorder characterized by a somatic mutation in the PIGA gene, leading to a deficiency of proteins linked to ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Paroxysmal nocturnal hemoglobinuria from bench to bedside

    ... hematopoietic stem cell (HSC) that acquires a somatic mutation in a gene called phosphatidylinositol glycan anchor biosynthesis, ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Current state of prognostication and risk stratification in myelodysplastic syndromes

    ... SUMMARY: How to best use the results of molecular mutation testing to inform clinical decision making in MDS is still a work ...

    Research Article last updated 03/02/2015 - 1:38pm.

  5. Personalized medicine for MDS

    ... example, a younger patient with a negative prognostic mutation may be considered for a more intensive treatment, such as ... About 20% of patients with del (5q) have a concurrent TP53 mutation which suggests more aggressive disease and should be treated ...

    Research Review last updated 05/02/2016 - 9:44am.

  6. Top expert calls future MDS/AML care “promising”

    ... about this. Let’s say you have a very particular mutation that happens in 1% or 2% of the patients with this disease. ... “OK, this is exactly what the patient has, this is the mutation that the patient has, etcetera.” Then, maybe you work with the ...

    Article last updated 11/02/2016 - 11:28am.

  7. Advances in the molecular pathology of MDS

    ... clinical practice. The frequent finding of more than one mutation in patients confirms that MDS are a group of heterogeneous ...

    Research Review last updated 05/02/2016 - 9:44am.

  8. Myelodysplastic syndromes: Contemporary review and how we treat

    ... MDS. Going forward, we believe it is time to incorporate mutation information in clinically derived prognostic models in MDS and ...

    Research Article last updated 04/29/2016 - 1:05pm.

  9. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

    ... shorter OS. Nearly one half of patients (46%) carried a mutation in TP53, DNMT3A, or TET2 and accounted for 64% of deaths. ...

    Research Article last updated 10/01/2014 - 10:59am.

  10. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... cells with strong p53 expression confirmed TP53 mutation , whereas cells with moderate expression were predominantly of ...

    Research Article last updated 04/23/2014 - 12:26pm.